

# Dawn Midwinter

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8346347/publications.pdf>

Version: 2024-02-01

8  
papers

220  
citations

1684188

5  
h-index

1720034

7  
g-index

8  
all docs

8  
docs citations

8  
times ranked

251  
citing authors

#	ARTICLE	IF	CITATIONS
1	Best Practice Management of Patients With Chronic Obstructive Pulmonary Disease: A Case-Based Review. <i>Journal for Nurse Practitioners</i> , 2022, , .	0.8	0
2	Validation of the Summit Lab Score in Predicting Exacerbations of Chronic Obstructive Pulmonary Disease Among Individuals with High Arterial Stiffness. <i>International Journal of COPD</i> , 2021, Volume 16, 41-51.	2.3	1
3	FEV <sub>1</sub> Minimum Important Difference versus Minimal Detectable Difference? In Search of the Unicorn. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 1573-1576.	5.6	6
4	Discordant diagnostic criteria for pneumonia in COPD trials: a review. <i>European Respiratory Review</i> , 2021, 30, 210124.	7.1	8
5	&lt;p&gt;Critical Error Frequency and the Impact of Training with Inhalers Commonly used for Maintenance Treatment in Chronic Obstructive Pulmonary Disease&lt;/p&gt;. <i>International Journal of COPD</i> , 2020, Volume 15, 1301-1313.	2.3	7
6	Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 1508-1516.	5.6	151
7	A randomized, open-label, single-visit crossover study simulating triple-drug delivery with Ellipta compared with dual inhaler combinations in patients with COPD. <i>International Journal of COPD</i> , 2018, Volume 13, 2515-2523.	2.3	28
8	A randomized trial of once-daily fluticasone furoate/vilanterol or vilanterol versus placebo to determine effects on arterial stiffness in COPD. <i>International Journal of COPD</i> , 2017, Volume 12, 351-365.	2.3	19